Govt proposes tighter scrutiny of antimicrobial drugs to address resistance worries

The government is proposing amendments to the New Drugs and Clinical Trials Rules, 2019 for antimicrobial medicines. This amendment would require manufacturers to seek permission from the Central Licensing Authority before obtaining state manufact...

New Delhi: The government has proposed an additional layer of regulatory scrutiny for antimicrobial medicines to address the growing threat of antimicrobial resistance (AMR), a move that industry experts warn could increase compliance costs for pharmaceutical manufacturers, particularly micro, small and medium enterprises (MSMEs), and potentially affect the availability and affordability of these medicines.

The proposed amendment to the New Drugs and Clinical Trials Rules, 2019, will require manufacturers to obtain permission from the Central Licensing Authority (CLA) before approaching state licensing authorities for manufacturing licences for antimicrobial products.

Tighter Scrutiny of Antimicrobial Drugs in Works to Address Resistance Worries


"The requirement will apply prospectively, with the government clarifying that existing manufacturing licences will remain valid and current licence holders will not have to seek fresh approvals," an official said.

The health and family welfare minitry has proposed the amendment through a draft notification seeking to include 'antimicrobials' in the definition of a 'new drug' under Rule 2(1)(w)(v) of the New Drugs and Clinical Trials Rules, 2019.

The ministry said the proposal was intended to serve as an additional regulatory safeguard against AMR by strengthening oversight of antimicrobial products and ensuring appropriate scrutiny of their quality, safety and efficacy before new manufacturing licences are granted.

ADVERTISEMENT
The amendment had been proposed in view of concerns regarding the grant of manufacturing licences for antimicrobial products without adequate regulatory scrutiny, including assessments such as bioavailability/bioequivalence and stability studies, the ministry said.
READ MORE
ADVERTISEMENT

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

More from our Partners

Loading next story
Business News › Industry › Healthcare/Biotech › Pharmaceuticals › Govt proposes tighter scrutiny of antimicrobial drugs to address resistance worries
Text Size:AAA
Success
This article has been saved

*

+